Aclaris Therapeutics, Inc. $ACRS Stock: BML Capital Management LLC Reduces Stake

BML Capital Management LLC decreased its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 8.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 10,955,000 shares of the biotechnology company’s stock after selling 1,020,000 shares during the period. Aclaris Therapeutics comprises 30.7% of BML Capital Management LLC’s investment portfolio, making the stock its largest position. BML Capital Management LLC owned approximately 0.08% of Aclaris Therapeutics worth $57,623,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Sei Investments Co. bought a new position in Aclaris Therapeutics in the 1st quarter valued at approximately $814,000. Bank of New York Mellon Corp purchased a new stake in Aclaris Therapeutics during the 2nd quarter valued at $1,495,000. Dimensional Fund Advisors LP increased its holdings in shares of Aclaris Therapeutics by 88.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 511,461 shares of the biotechnology company’s stock worth $1,914,000 after purchasing an additional 240,611 shares in the last quarter. Palo Alto Investors LP bought a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth $8,535,045. Finally, Deutsche Bank AG bought a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth $5,507,000. Institutional investors own 98.34% of the company’s stock.

Wall Street Analysts Forecast Growth

ACRS has been the subject of several recent analyst reports. Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Canaccord Genuity Group increased their price objective on Aclaris Therapeutics from $10.00 to $13.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Wedbush reduced their price objective on Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Wednesday, October 28th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $11.33.

Aclaris Therapeutics Stock Performance

Aclaris Therapeutics stock opened at $3.92 on Friday. The stock has a market cap of $621.76 million, a PE ratio of -6.76 and a beta of 0.96. Aclaris Therapeutics, Inc. has a one year low of $2.25 and a one year high of $6.60. The stock has a fifty day moving average of $4.43 and a 200 day moving average of $4.53.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.04. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%. As a group, sell-side analysts predict that Aclaris Therapeutics, Inc. will post -0.56 EPS for the current fiscal year.

About Aclaris Therapeutics

Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.